



Descriptive report of Adverse Events (ADEs)

Data in Saudi Arabia, 2026

DATA CAPTURE SECTION
NATIONAL PHARMACOVIGILANCE CENTER





General notes:

Data Report: National Pharmacovigilance Centre

- **Source:** Dashboard for Reports of Drug and Vaccine ADEs & Spontaneous Vigilance System, National Pharmacovigilance Centre
- **Scope:** Adverse event reports, these are medical occurrences noted after the use of a medication, but not necessarily imply a direct causal link to the drug.
- **Parameters:**
 1. Drug reports only (vaccine reports excluded)
 2. Data extract from 1 Jan to 31 March 2026.


Understanding Pharmacovigilance:

The National Pharmacovigilance Centre plays a crucial role in post-market drug safety monitoring. By collecting and analyzing adverse drug event reports, it helps identify potential safety signals and facilitates interventions to protect public health.


Important Notes:

It's vital to understand that reports of adverse events following drug use do not automatically prove the drug caused the event. Careful assessment is needed to establish any potential relationship.


Number of ADEs in the system




Number of Reports Based on Organization Type




Reports seriousness




Report count by Gender




Top 5 reported Drugs (by Generic Name)



Top 5 reported ADEs (by MedDRA description)



*AST=Aspartate Aminotransferase



MOD: Ministry of Defense, MAH: Marketing Authorization Holders, MOH: Ministry of Health, JHAH: Johns Hopkins Aramco Healthcare, MOI: Ministry of Interior, KFSHRC: King Faisal Specialist Hospital and Research Centre

